ADHERE-S (NIS Brilique)

AstraZeneca

Status: Completed

Conditions: ACS (Acute Coronary Syndrome)

Treatments: Drug: ticagrelor 90 mg

Study type: Observational

Funder types: Industry

Identifiers

NCT03444012

D5130R00052

Details and patient eligibility

About

noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia

Enrollment: 269 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥ 18 years of age
• diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively treated
• Patients already on treatment with ticagrelor at least for 1 month and no longer than 3 months prior to study initiation. Enrolment in this study must not be trigger for ticagrelor initiation.
• read and signed the Informed Consent Form

Exclusion criteria

Any contraindications as per approved SmPC of Brilique

• Patients with life-threatening conditions which could disable patients to comply with scheduled visits and/or not able to fill in the patient questionnaires.